- abnormal leukocyte migration / MGI
- impaired macrophage phagocytosis / MGI
- liver inflammation / MGI
- lung inflammation / MGI
- decreased myocardial infarction size / MGI
- enhanced coordination / MGI
- increased mean systemic arterial blood pressure / MGI
- impaired natural killer cell mediated cytotoxicity / MGI
- increased circulating tumor necrosis factor level / MGI
- increased circulating interferon-gamma level / MGI
- increased circulating interleukin-2 level / MGI
- decreased transforming growth factor level / MGI
- decreased sensitivity to induced cell death / MGI
- increased sensitivity to induced morbidity/mortality / MGI
- abnormal circulating cytokine level / MGI
- decreased activation-induced cell death of T cells / MGI
- increased susceptibility to induced arthritis / MGI
- abnormal vasculogenesis / MGI
- delayed wound healing / MGI
- peritoneal inflammation / MGI
- decreased tumor growth/size / MGI
- abnormal physiological neovascularization / MGI
- abnormal vascular endothelial cell physiology / MGI
- decreased susceptibility to kidney reperfusion injury / MGI
- abnormal miniature excitatory postsynaptic currents / MGI
- decreased acute inflammation / MGI
- decreased circulating creatinine level / MGI
- decreased blood urea nitrogen level / MGI
- decreased angiogenesis / MGI
- abnormal vascular endothelial cell morphology / MGI
- decreased circulating tumor necrosis factor level / MGI
- increased tumor necrosis factor secretion / MGI
- abnormal interleukin secretion / MGI
- increased interleukin-1 beta secretion / MGI
- increased interleukin-10 secretion / MGI
- increased interleukin-6 secretion / MGI
- abnormal chemokine secretion / MGI
- abnormal circulating chemokine level / MGI
- abnormal cell morphology / MGI
- abnormal definitive hematopoiesis / MGI
- increased susceptibility to parasitic infection / MGI
- immune system phenotype / MGI
- abnormal vascular smooth muscle physiology / MGI
- abnormal cell physiology / MGI
- increased mitochondria size / MGI
- abnormal mitochondrial crista morphology / MGI
- decreased fibroblast proliferation / MGI
B6.129P2-Cd44tm1Mak/Cnbc
Status | Available to order |
EMMA ID | EM:06743 |
International strain name | B6.129P2-Cd44tm1Mak/Cnbc |
Alternative name | CD44 |
Strain type | Targeted Mutant Strains : Knock-out |
Allele/Transgene symbol | Cd44tm1Mak, |
Gene/Transgene symbol | Cd44 |
Information from provider
Provider | Tak W Mak |
Provider affiliation | Mak Lab, Campbell Family Breast Cancer reseach Institute |
Genetic information | Targeting vector replaces 3' end of exon 2 and the entire exon 3 with a neomycin resistance gene in an antisense orientation containing several stop codons for all reading frames. |
Phenotypic information | Mice were born in Mendelian ratio without any obvious developmental or neurological deficits. Hematological impairment was evidenced by altered tissue distribution of myeloid progenitors with increased levels of colony-forming unit granulocyte-macrophage (CFU-GM) in bone marrow and reduced numbers of CFU-GM in spleen. Fetal liver colony-forming unit spleen and granulocyte colony-stimulating factor mobilization assays, together with reduced CFU-GM in peripheral blood, suggested that progenitor egress from bone marrow was defective. |
Breeding history | Backcross into C57BL/6 10X. |
References |
|
Homozygous fertile | yes |
Homozygous viable | yes |
Homozygous matings required | no |
Immunocompromised | no |
Information from EMMA
Archiving centre | CNB-CSIC, Centro Nacional de Biotecnologia, Madrid, Spain |
Animals used for archiving | homozygous C57BL/6J |
Disease and phenotype information
MGI phenotypes (allele matching)
Literature references
- CD44 regulates hematopoietic progenitor distribution, granuloma formation, and tumorigenicity.;Schmits R, Filmus J, Gerwin N, Senaldi G, Kiefer F, Kundig T, Wakeham A, Shahinian A, Catzavelos C, Rak J, Furlonger C, Zakarian A, Simard J J, Ohashi P S, Paige C J, Gutierrez-Ramos J C, Mak T W, ;1997;Blood;90;2217-33; 9310473
- Absence of the CD44 gene prevents sarcoma metastasis.;Weber Georg F, Bronson Roderick T, Ilagan John, Cantor Harvey, Schmits Rudolf, Mak Tak W, ;2002;Cancer research;62;2281-6; 11956084
INFRAFRONTIER® and European Mouse Mutant Archive - EMMA® are registered trademarks at the European Union Intellectual Property Office (EUIPO).